Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ …
MJ Pontecorvo, M Lu, SC Burnham, AE Schade… - JAMA …, 2022 - jamanetwork.com
Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of
donanemab treatment with plasma biomarkers associated with Alzheimer disease. Design,
Setting, and Participants TRAILBLAZER-ALZ was a randomized, double-blind, placebo-
controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56
sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc …
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of
donanemab treatment with plasma biomarkers associated with Alzheimer disease. Design,
Setting, and Participants TRAILBLAZER-ALZ was a randomized, double-blind, placebo-
controlled clinical trial conducted from December 18, 2017, to December 4, 2020, across 56
sites in the US and Canada. Exploratory biomarkers were prespecified with the post hoc …